HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Blood pressure lowering for kidney transplant recipients: systematic review with network meta-analysis.

AbstractOBJECTIVE:
Hypertension affects 50-90% of kidney transplant recipients and is associated with cardiovascular disease and graft loss. We aimed to evaluate the comparative benefits and harms of blood pressure lowering agents in people with a functioning kidney transplant.
METHODS:
We conducted a systematic review with network meta-analysis of randomized controlled trials (RCTs). We searched MEDLINE, Embase, and CENTRAL through to October 2023. RCTs evaluating blood pressure lowering agents administered for at least 2 weeks in people with a functioning kidney transplant with and without preexisting hypertension were eligible. Two reviewers independently extracted data. The primary outcome was graft loss. Treatment effects were estimated using random effects network meta-analysis, with treatment effects expressed as an odds ratio (OR) for binary outcomes and mean difference (MD) for continuous outcomes together with their 95% confidence interval (CI). Confidence in the evidence was assessed using GRADE for network meta-analysis.
RESULTS:
Ninety-four studies (7547 adults) were included. Two studies were conducted in children. No blood pressure-lowering agent reduced the risk of graft loss, withdrawal because of adverse events, death, cardiovascular or kidney outcomes compared with placebo/other drug class. Angiotensin-converting enzyme inhibitors and angiotensin receptor blocker therapy may incur greater odds of hyperkalemia compared with calcium channel blockers [odds ratio (OR) 5.48, 95% confidence interval (CI) 2.47-12.16; and OR 8.67, 95% CI 2.65-28.36; low certainty evidence, respectively).
CONCLUSION:
The evidentiary basis for the comparative benefits and safety of blood pressure lowering agents in people with a functioning kidney transplant is limited to guide treatment decision-making.
AuthorsPatrizia Natale, Suetonia C Palmer, Allison Jaure, Valeria Saglimbene, Andrea Iannone, Amanda Sluiter, Jonathan Craig, Giovanni F M Strippoli
JournalJournal of hypertension (J Hypertens) Vol. 42 Issue 5 Pg. 848-855 (May 01 2024) ISSN: 1473-5598 [Electronic] Netherlands
PMID38230619 (Publication Type: Meta-Analysis, Systematic Review, Journal Article)
CopyrightCopyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Chemical References
  • Angiotensin-Converting Enzyme Inhibitors
Topics
  • Child
  • Adult
  • Humans
  • Blood Pressure
  • Kidney Transplantation (adverse effects)
  • Network Meta-Analysis
  • Hypertension (drug therapy)
  • Angiotensin-Converting Enzyme Inhibitors (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: